Innovation Coffee: Advancements in REMaST® Therapy and the Mission to Regenerate Nervous Tissue.

Dec 5, 2023 | News

In the context of the “Healing the Incurable” Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the research of our revolutionary REMaST® therapy in an interview conducted at the Innovation Center of Intesa San...

Scientific Venture Capital Selects Hemera Among Italy’s Most Innovative Deep-Tech Companies

Nov 9, 2023 | News

Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative scientific entrepreneurial initiatives in Italy by the investment holding company Scientific Venture Capital. This firm...

Hemera Pharma: Excellence and Innovation Recognized with Women Startup Award in Regenerative Medicine

Sep 29, 2023 | News

Hemera Pharma Receives Women Startup Award for Excellence in Regenerative Medicine We are delighted to share Hemera Pharma’s recent achievements in the field of regenerative medicine. On September 29, amidst the prestigious setting of OGR Torino, Hemera Pharma...

Hemera Pharma among the 50 most innovative companies of the 2023 “Premio Gamma Donna”

Jun 22, 2023 | Events, News

Cristiana Vignoli in the shortlist of the FAB50, the 50 most innovative female entrepreneurs of the “PremiO Gamma Donna” We are pleased to announce that our Chief Executive Officer Cristiana Vignoli has been included in the prestigious FAB50 short list of...

Hemera receives Orphan Drug Designation for REMaST® therapy

Jun 8, 2023 | News

REMaST® recognized as an orphan drug for acute spinal injuries The advanced cell therapy REMaST® developed by Hemera has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...

Changed the structure of the Board of Directors

May 8, 2023 | News

Hemera’s Board of Directors: Updates in its structure For personal reasons, Aldo Cocchiglia is leaving the Board of Directors, effective May 3, 2023. Two years after the birth of Hemera, the shareholders express their gratitude to Ing. Cocchiglia for his...